Epithelial ovarian cancer
Drug research and approvals for epithelial ovarian cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 600 studies of epithelial ovarian cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 600
- Trials authorized in Canada: 26
- FDA orphan approvals: 0
- EU medicines: 0
- A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of…NCT07940881 · Phase 1 · SystImmune Inc. · starts Aug 24, 2026
- A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsNCT07923214 · Phase 1 · Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · starts Jul 2, 2024
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- Phase 1 Study of VT-101 in Advanced Ovarian CancerNCT07905677 · Phase 1 · Michael J. Goodheart · starts Oct 26, 2026
- Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersNCT07902375 · Not applicable · Universiteit Antwerpen · starts Jun 19, 2026
- Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian,…NCT07896421 · Not reported · AbbVie · starts Oct 21, 2026
- Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian CancerNCT07889843 · Not reported · Hellenic Cooperative Oncology Group · starts Jul 10, 2026
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsNCT07883798 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Oct 6, 2026
- EHR Intervention to Increase HBOC Genetic TestingNCT07876349 · Not applicable · Columbia University · starts Sep 1, 2026
How its trials ended
1,869 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 437 whose ending is known, 28% met their primary endpoint, 11% missed it and 61% stopped early.
- Completed, result not reported63134%
- Ongoing53529%
- Status unknown26614%
- Stopped: other or unclear1267%
- Met its primary endpoint1237%
- Stopped: enrollment or feasibility553%
- Missed its primary endpoint473%
- Stopped: sponsor or business decision412%
- Stopped: lack of efficacy292%
- Stopped: funding131%
- Stopped: safety3<1%
| Sep 23, 2026 | A phase 3, open-label, multicenter, randomized study of raludotatug deruxtecan (MK-5909, r-dxd) with or without bevacizumab versus standard-of-care…Raludotatug deruxtecan (MK-5909) / Avastin (bevacizumab) / Mvasi (bevacizumab) | Merck & Co. (MSD) | Pending |
| Aug 20, 2026 | A randomised, open-label, phase III study of torvutatug samrotecan in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance…Torvutatug samrotecan (AZD5335) / Avastin (bevacizumab) / Vegzelma (bevacizumab) | AstraZeneca Pharmaceuticals | Pending |
| Dec 23, 2025 | A phase 1b/2 open-label, multicenter study to evaluate the safety and efficacy of raludotatug deruxtecan with or without other anticancer investigational…MK-5909 (raludotatug deruxtecan (r-dxd)) / Keytruda / Bevacizumab / Paclitaxel… | Merck & Co. (MSD) | Ongoing |
| Oct 20, 2025 | A randomised, open-label, phase III study of AZD5335 versus mirvetuximab soravtansine in fr-high and AZD5335 versus investigator’s choice chemotherapy in…AZD5335 | AstraZeneca Pharmaceuticals | Ongoing |
| Mar 29, 2023 | A phase 2 open-label study evaluating the efficacy and safety of luveltamab tazevibulin (STRO-002) in women with relapsed platinum-resistant epithelial ovarian…Luveltamab tazevibulin (STRO-002) | Sutro Biopharma | Ongoing |
| Jan 18, 2023 | A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced, platinum-resistant high-grade epithelial…Relacorilant (CORT125134) / Paclitaxel | Corcept Therapeutics | Ongoing |
| Dec 30, 2022 | 68ga-fapi pet/ct in the staging of high grade epithelial ovarian cancers: a pilot study68GA-PNT6555 [manufacturer designation: [GA-6S[-PNT65S5 injection] | Princess Margaret Cancer Centre | Ongoing |
| Dec 14, 2022 | Phase 1 first-in-human study to explore the safety, tolerability, and pharmacokinetics of amg 794 in subjects with claudin 6 positive advanced/metastatic non…Amg 794 | Amgen | Pending |
| Nov 9, 2022 | Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy…Mirvetuximab soravtansine | AbbVie | Ongoing |
| Sep 29, 2022 | Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate…Mirvetuximab soravtansine (IMGN853) | AbbVie | Ongoing |
| Nov 25, 2003 | AbagovomabTreatment of epithelial ovarian cancer | Menarini Ricerche S.p.A. | Designated |
| Feb 11, 2002 | Recombinant immunotoxin combining the functional components…Treatment of epithelial ovarian cancer | National Institutes of Health | Designated |
| Nov 25, 1996 | Monoclonal antibody-B43.13Treatment of epithelial ovarian cancer. | CanariaBio Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA